Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

iShares Biotechnology ETF (NQ:IBB)

213.56 +2.73 (+1.29%)
Official Closing Price Updated: 4:15 PM EDT, Aug 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about iShares Biotechnology ETF

< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
28 29 Next >
News headline image
The Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Can Silver (SLV) Follow Meme Stocks Higher? ↗
SLV could be gearing up for another move if the other indices begin to break their 50-DMA. 
Via Talk Markets
News headline image
The Daily Biotech Pulse: Pfizer Reports Positive Ulcerative Colitis Study Data, Novavax COVID Shot Authorized For Adolescents In India, Argenx Stock Sale ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
Major Sector ETFs Need to Clear Resistance ↗
Last year's dip-buying was all the rage as a large portion of the market ran rich with money provided by the Fed. Now traders are finding the market tough to navigate with weak trends that can easily... 
Via Talk Markets
News headline image
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Pfizer Strikes COVID-19 Pill Supply Deal, Argenx Reports Positive Late-Stage Readout ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
The Best Potential Trade Setup Looking Ahead: FXE Euro Trust ↗
The Euro is 20-years old as of January this year. It is the official currency of 19 of the 27 members of the European Union. After the U.S. dollar, it’s the second-largest and second most traded... 
Via Talk Markets
News headline image
How do Biotechnology Funds and ETFs Perform Over Five Years? ↗
Biotech investing can be difficult for short-term traders but can offer good returns over five years if balanced with other healthcare positions like the XLV. 
Via Talk Markets
News headline image
The Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & Earnings ↗
Biotech stocks rebounded along with the broader market in the week ending March 18, as risk appetite returned. Multiple conference presentations, clinical readouts and earnings news dictated sentiment... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Moderna Files For 2nd COVID Booster Shot Authorization, Lexicon Secures Debt Funding, Amneal Gets Sub-License to Manufacture Generic COVID Pill ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
The Daily Biotech Pulse: AbbVie's Rinvoq Gets Label Expansion, AstraZeneca COVID Antibody Cocktail Authorized By UK Regulator, Stealth Touts Positive Data ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Rates Increase and Transportation (IYT) Clears its Major Moving Averages ↗
The market rallied into the Feds rate announcement, showing the speculator's optimism given the current downward trend. 
Via Talk Markets
News headline image
The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Reaching The Breaking Point in the Nasdaq 100 (QQQ) ↗
With a tough trading week ahead, if the QQQ is going to break down further, watch for other indices to follow and break their key support levels as confirmation. 
Via Talk Markets
News headline image
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings ↗
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Valneva Gains On COVID Shot Regulatory Update, Lucira Health And Clearside Jump On Earnings, BeiGene Drug Snags Approval In China ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Valneva Says Confident Of Conditional Approval For COVID Vaccine Candidate In... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Pfizer Begins Late-Stage Pediatric COVID Pill Study, Midatech And J&J Unit Expand R&D Collaboration, AbbVie-Alvotech Settle Humira Dispute ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus AbbVie Settles With Alvotech On Humira Biosimilar Patent Dispute AbbVie, Inc... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Moderna Outlines Steps For mRNA Tech Advancement, Voyager-Novartis Strike Licensing Deal, Valneva Reports Positive Chikungunya Shot Readout ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Moderna Announces 4 Initiatives To Advance mRNA Vaccines As Preventative... 
Via Benzinga
News headline image
Are U.S Treasury Bonds (TLT) a Lagging Safety Play? ↗
Currently, the 20+ Year Treasury bond ETF is beginning to trend upwards, however, it has a lot of overhead resistance from the 50-Day moving average at $141.23, and the 200-Week MA at $140.91. 
Via Talk Markets
News headline image
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg ↗
Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Ocugen Faces Regulatory Setback, vTv CEO Quits, Biogen-Eisai Make Headway With Second Alzheimer's Antibody Treatment In Japan ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Merck's Keytruda Evaluated In Combination With Microbiome Therapeutic In... 
Via Benzinga
News headline image
The Daily Biotech Pulse: NuCana Shelves Biliary Tract Cancer Study, Tricida Data Readout Pushed Back Due to Ukrainian Crisis, Synlogic Names New CFO ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus NuCana Discontinues Biliary Tract Cancer Study Following Futility Analysis... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Karyopharm Flags Delay In Selinexor Label Expansion, Finch, Celyad Hit With Clinical Holds, Adagene Strikes R&D Collaboration With Sanofi ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Karyopharm Says FDA Mandates Additional Study For Expanding Selinexor Label... 
Via Benzinga
News headline image
Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates ↗
The Food and Drug Administration approval calendar was light in February. Nevertheless, the month saw regulatory nods accorded to some breakthrough therapies. Agios... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight ↗
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Lilly's Jardiance Gets Nod For Heart Failure, Pulmatrix Announces Reverse Split, Reata Awaits FDA Decision ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Lilly's Co-developed Diabetes Drug Jardiance Gets Label Expansion To... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (... 
Via Benzinga
News headline image
Why you must Choose a Trading Timeframe ↗
Jumping in the market without a trading style and timeframe makes it much easier to lose money if the market turns around and catches you without a plan for your trade. 
Via Talk Markets
News headline image
The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase... 
Via Benzinga
< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
28 29 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.